Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * Patients who will undergo staged liver resections are included in this study. In these cases, preoperative MEDI6469 will be given prior to the initial procedure. * Patients with small \<3 cm tumors located \>2 cm away from central bile ducts will be considered for either radiofrequency ablation or resection, the choice of which will be determined at the time of surgery. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Laboratory values during preoperative assessment within the protocol specified range * Ability to give informed consent and comply with the protocol. Patients with a history of psychiatric illness must be judged able to understand the investigational nature of the study and the risks associated with the therapy. * No active gastrointestinal bleeding. * No clinical or laboratory coagulopathy * Anticipated lifespan greater than 12 weeks Exclusion Criteria: * Metastatic disease outside of the liver that is not considered surgically resectable or curable. * Active infection. * Active autoimmune disease including patients with Inflammatory Bowel Disease as determined by an autoimmune questionnaire. * Previous treatment with mouse monoclonal antibodies. * Need for chronic maintenance oral steroids. * Any medical or psychiatric condition that in the opinion of the PI would preclude compliance with study procedures. * Enrollment in a clinical trial in which a different investigational agent is administered within 4 weeks prior to the first dose of MEDI6469.